NM_000249.4:c.1990-3C>G
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM2PP3_ModeratePP5
The NM_000249.4(MLH1):c.1990-3C>G variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000249.4 splice_region, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:2
- -
- -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1990-3C>G intronic variant results from a C to G substitution 3 nucleotides upstream from coding exon 18 in the MLH1 gene. This variant was identified in an individual diagnosed with colorectal cancer (CRC) at age 32 and in two of his relatives who were also diagnosed with CRC. RT-PCR analysis of patient RNA in the same study was reported to cause a defective exon 18 splice acceptor site with activation of a cryptic splice acceptor site in intron 17, which resulted in the incorporation of 83 nucleotides of intron 17 in the mature mRNA (data were not shown, Güran S et al. Cancer Genet Cytogenet, 2005 Jul;160:164-8). This variant has been identified in a proband whose Lynch syndrome-associated tumor demonstrated loss of MLH1/PMS2 expression by immunohistochemistry (IHC), where MLH1 promotor hypermethylation was negative (Ambry internal data). This alteration has also been identified as somatic in conjunction with a somatic pathogenic MLH1 variant in a CRC tumor with loss of MLH1/PMS2 expression by IHC, where MLH1 promotor hypermethylation was negative (Ambry internal data). This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site; however, direct evidence is insufficient at this time (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
This sequence change falls in intron 17 of the MLH1 gene. It does not directly change the encoded amino acid sequence of the MLH1 protein, but it affects a nucleotide within the consensus splice site of the intron. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individual(s) with colorectal cancer (PMID: 15993273). It has also been observed to segregate with disease in related individuals. This variant is also known as IVS17-3C>G in the literature. ClinVar contains an entry for this variant (Variation ID: 89988). This variant has been reported to have conflicting or insufficient data to determine the effect on MLH1 protein function (PMID: 15993273). Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at